Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes REPLY

被引：1
|
作者：
Zinman, Bernard [1 ]
Lachin, John M. [2 ]
Inzucchi, Silvio E. [3 ]
机构：
[1] Univ Toronto, Toronto, ON, Canada
[2] George Washington Univ, Ctr Biostat, Rockville, MD USA
[3] Yale Univ, Sch Med, New Haven, CT USA
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2016年 / 374卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1094 / 1094
页数：1
相关论文
共 50 条
  • [21] Comparison of Cardiovascular Outcomes Between Dapagliflozin and Empagliflozin in Patients With Type 2 Diabetes: A Meta-Analysis
    Memon, Rahat A.
    Akbariromani, Hanieh
    Vohra, Rimsha R.
    Kundi, Hayan
    Saleem, Rao Faraz
    Ghaffari, Muhammad Abuzar
    Haas, Donald
    Khan, Areeba
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (07)
  • [22] Once-Weekly Exenatide and Cardiovascular Outcomes in Type 2 Diabetes Reply
    Holman, Rury R.
    Bethel, M. Angelyn
    Hernandez, Adrian F.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (25): : 2502 - 2502
  • [23] Cardiovascular Outcomes With Empagliflozin and Dapagliflozin in Patients Without Diabetes
    Singh, Sahib
    Garg, Aakash
    Tantry, Udaya S.
    Bliden, Kevin
    Gurbel, Paul A.
    Gulati, Martha
    AMERICAN JOURNAL OF CARDIOLOGY, 2024, 218 : 24 - 31
  • [24] Comparison of cardiovascular and renal outcomes between dapagliflozin and empagliflozin in patients with type 2 diabetes without prior cardiovascular or renal disease
    Lim, Jayoung
    Hwang, In-Chang
    Choi, Hong-Mi
    Yoon, Yeonyee E.
    Cho, Goo-Yeong
    PLOS ONE, 2022, 17 (10):
  • [25] Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease
    Wanner, Christoph
    Lachin, John M.
    Inzucchi, Silvio E.
    Fitchett, David
    Mattheus, Michaela
    George, Jyothis
    Woerle, Hans J.
    Broedl, Uli C.
    von Eynatten, Maximilian
    Zinman, Bernard
    Aizenberg, D.
    Ulla, M.
    Waitman, J.
    De Loredo, L.
    Farias, J.
    Fideleff, H.
    Lagrutta, M.
    Maldonado, N.
    Colombo, H.
    Ferre Pacora, F.
    Wasserman, A.
    Maffei, L.
    Lehman, R.
    Selvanayagam, J.
    d'Emden, M.
    Fasching, P.
    Paulweber, B.
    Toplak, H.
    Luger, A.
    Drexel, H.
    Prager, R.
    Schnack, C.
    Schernthaner, G.
    Fliesser-Goerzer, E.
    Kaser, S.
    Scheen, A.
    Van Gaal, L.
    Hollanders, G.
    Kockaerts, Y.
    Capiau, L.
    Chachati, A.
    Persu, A.
    Hermans, M.
    Vantroyen, D.
    Vercammen, C.
    Van de Borne, P.
    Mathieu, C.
    Benhalima, K.
    Lienart, F.
    Mortelmans, J.
    CIRCULATION, 2018, 137 (02) : 119 - 129
  • [26] Changes in cardiac and vascular haemodynamics as potential mediators of improvements in cardiovascular and kidney outcomes with empagliflozin in type 2 diabetes
    Kramer, Bernhard K.
    Hauske, Sibylle J.
    Chilton, Robert
    Mann, Johannes F. E.
    Gullestad, Lars
    Fitchett, David
    Mattheus, Michaela
    Steubl, Dominik
    Wanner, Christoph
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2023, 37 (09)
  • [27] Microalbuminuria and mortality in type 2 diabetes - Reply
    Barry, HC
    JOURNAL OF FAMILY PRACTICE, 1998, 47 (02): : 89 - 90
  • [28] Diabetes Medications and Cardiovascular Outcomes in Type 2 Diabetes
    Chi, Cecilia
    Snaith, Jennifer
    Gunton, Jenny E.
    HEART LUNG AND CIRCULATION, 2017, 26 (11): : 1133 - 1141
  • [29] Cardiovascular and mortality events in type 2 diabetes cardiovascular outcomes trials: a systematic review with trend analysis
    Lorenzo M. Vetrone
    Francesco Zaccardi
    David R. Webb
    Sam Seidu
    Nitin N. Gholap
    Dario Pitocco
    Melanie J. Davies
    Kamlesh Khunti
    Acta Diabetologica, 2019, 56 : 331 - 339
  • [30] Cardiovascular and mortality events in type 2 diabetes cardiovascular outcomes trials: a systematic review with trend analysis
    Vetrone, Lorenzo M.
    Zaccardi, Francesco
    Webb, David R.
    Seidu, Sam
    Gholap, Nitin N.
    Pitocco, Dario
    Davies, Melanie J.
    Khunti, Kamlesh
    ACTA DIABETOLOGICA, 2019, 56 (03) : 331 - 339
12345